GRAIL, founded in 2016, is a healthcare company focused on early cancer detection. Its core technology integrates next-generation sequencing, population-scale clinical studies, and machine learning to identify cancer at treatable stages. The company's primary product is Galleri, a multi-cancer early detection blood test capable of identifying signals from over 50 types of cancers - more than 45 of which lack recommended screening methods today - from a single blood draw.
The company's technical work spans genomics, software engineering, and automation. Its clinical study program is one of the largest in genomic medicine. GRAIL operates as a multi-disciplinary organization of scientists, engineers, and physicians, and collaborates with health systems, academic medical centers, and pharmaceutical companies worldwide.
GRAIL is headquartered in Menlo Park, California, with additional offices in Washington, D.C., North Carolina, and the United Kingdom.
